Comparative Pharmacology
Head-to-head clinical analysis: IMATINIB MESYLATE versus RETEVMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMATINIB MESYLATE versus RETEVMO.
IMATINIB MESYLATE vs RETEVMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imatinib mesylate is a tyrosine kinase inhibitor that selectively inhibits BCR-ABL, c-KIT, and PDGFR tyrosine kinases, thereby blocking signal transduction pathways involved in cellular proliferation and survival.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
400 mg orally once daily, with a meal and a large glass of water. Dose escalation to 600 mg or 800 mg daily may be considered in cases of disease progression.
160 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 18 hours (range 13–22 hours) for the parent drug; the active metabolite N-desmethyl imatinib has a half-life of about 40 hours. Clinically, this supports once-daily dosing.
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Primarily fecal (68% of dose) as metabolites; renal excretion accounts for approximately 13% of dose (5% as unchanged drug and 8% as metabolites).
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor